We are driven to design solutions solely focused on the aorta. We’re redefining the treatment of aortic disease by extending the reach of endovascular solutions as far as medically and humanly possible.

Resource Center

Endovascular Today Supplement

Experts discuss the versatility of RelayPlus in TEVAR.

Upcoming Events

21st European Vascular Course (EVC)

Mar 5-7, 2017 | Maastricht, The Netherlands

International Symposium on Endovascular Therapeutics (SITE)

Mar 29-31, 2017 | Barcelona, Spain

Congreso Internacional de Cirugía Endovascular (CICE)

Apr 5-8, 2017 | Sao Paulo, Brazil


WerfenLife is a multinational group of companies, headquartered in Barcelona and multinational in scope, operating directly in over 30 countries and more than 80 territories via distributors. It is devoted to the R&D, production and distribution of highly specialised products for health and the life sciences. Its product portfolio includes in vitro diagnostics, where it is world leader in coagulation, critical care and autoimmunity, medical devices and scientific instrumentation. With a total workforce of around 5,000, it has R&D and production centers in Spain and the United States.

For further information, visit www.werfenlife.com.

*TREO, Abdominal Stent-Graft System is certified by SGS (0120) according to Council Directive 93/42/EEC as amended 2007/47/EC.  U.S. Caution, limited by United States law to investigational use only.